fbpx Skip to main content

Biocom California Newsletter Article

Take a look at how this year’s Life Science Catalyst Award recipients are transforming and progressing the industry as we know it today.

Catalyst Award Winner: Alice Zhang

  • 2021-11-17T20:00:00.000+0000
  • California
  • Author: Canale Communications

Catalysts are defined by their ability to provoke change or increase the rate of significant action. Scientifically speaking, catalysts often make chemical reactions more energetically efficient. Similarly, an effective leader can create greater efficiency, productivity and innovation within an organization. That’s why Biocom California has, for the last six years, recognized and honored those within the Golden State who are sparking lasting change in the life science community. These trailblazers have blended youthful exuberance with a veteran presence to usher in the future of healthcare. Take a look at how this year's Life Science Catalyst Award recipients are transforming and progressing the industry as we know it today.

Alice Zhang | CEO and Co-founder of Verge Genomics

Alice is no stranger to prestigious awards, having already been named a San Francisco Business Times’ 40 Under 40, MIT Technology Review’s Innovator Under 35 and Forbes 30 Under 30 Featured Honoree. Long before she founded Verge Genomics, she spent years gaining experience and carving pathways in the industry through her time at the National Cancer Institute, the Lewis-Sigler Institute for Integrative Genomics at Princeton University and the University of California, Los Angeles (UCLA). During her time in the field, she’s authored several papers on gene networks involved in neuroregeneration and now pays it forward by operating as an angel investor and advisor for startups that explore the nuances and innovative potential of biotechnology. Verge Genomics, her main venture, prides itself on utilizing human genomics to create transformational genetic therapies. Verge’s intention is to target genetic pathways shared across several patients. In doing so, their treatments will have the potential to extend their viability beyond rare genetic populations into broader patient populations. Alice and her team truly are on the verge of astonishing breakthroughs in the life sciences.